Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Association Between the CYP2C9 Genotype and Hypoglycemia Among Patients With Type 2 Diabetes Receiving Sulfonylurea Treatment: A Meta-analysis.

Clinical therapeutics - 1 May 2021

Yee Jeong, Heo Yunhee, Kim Hamin, Yoon Ha Young, Song Gonjin, Gwak Hye Sun

Abstract excerpt

PURPOSE: Two common variants, CYP2C9*2 (Arg144Cys, rs1799853) and CYP2C9*3 (Ile359Leu, rs1057910), are known to reduce the catalytic function of the CYP2C9 enzyme. Because impaired catalytic function is likely to affect sulfonylurea metabolism, it is predictable that CYP2C9 loss-of-function alleles may increase the risk of sulfonylurea-induced hypoglycemia. This systematic review and meta-analysis aimed to assess...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Alleles
Share to Cytochrome P-450 CYP2C9
Share to Diabetes Mellitus, Type 2
Share to Genotype
Share to Hypoglycemia
Share to Sulfonylurea Compounds

Source

Identifiers

PMID: 33840516
DOI: 10.1016/j.clinthera.2021.03.008

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Association Between the CYP2C9 Genotype and Hypoglycemia Among Patients With Type 2 Diabetes Receiving Sulfonylurea Treatment: A Meta-analysis.PMID 33840516Read ↗

Presence of CYP2C9*3 allele increases risk for hypoglycemia in Type 2 diabetic patients treated with sulfonylureas.Semantic proximity Read ↗

CYP2C9, KCNJ11 and ABCC8 polymorphisms and the response to sulphonylurea treatment in type 2 diabetes patients.Semantic proximity Read ↗

Association of CYP2C9*2 Allele with Sulfonylurea-Induced Hypoglycemia in Type 2 Diabetes Mellitus Patients: A Pharmacogenetic Study in Pakistani Pashtun PopulationSemantic proximity Read ↗

Impact of clinical factors and CYP2C9 variants for the risk of severe sulfonylurea-induced hypoglycemia.Semantic proximity Read ↗

CYP2C19 Loss‐of‐function Polymorphisms are Associated with Reduced Risk of Sulfonylurea Treatment Failure in Chinese Patients with Type 2 DiabetesSemantic proximity Read ↗

CYP2C93 variant is associated with antidiabetes efficacy of gliclazide in Chinese type 2 diabetes patients.Semantic proximity Read ↗

CYP2C9*2 allele increases risk for hypoglycemia in POR*1/*1 type 2 diabetic patients treated with sulfonylureas.Semantic proximity Read ↗

Association between CYP2C9 slow metabolizer genotypes and severe hypoglycaemia on medication with sulphonylurea hypoglycaemic agents.Semantic proximity Read ↗

Possible approaches to CYP2C9-guided prescription of sulfonylureas in Russia.Semantic proximity Read ↗

Loss-of-function CYP2C9 variants improve therapeutic response to sulfonylureas in type 2 diabetes: a Go-DARTS study.Semantic proximity Read ↗

Interaction between variants in the CYP2C9 and POR genes and the risk of sulfonylurea-induced hypoglycaemia: A GoDARTS Study.Semantic proximity Read ↗

Pharmacogenetics of hypoglycemia associated with sulfonylurea therapy in usual clinical careSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.